O-Specific Polysaccharide Responses and Cholera
$248,922R56FY2020AINIH
Massachusetts General Hospital, Boston MA
Investigators
Linked publications & trials
Paper 39217775Paper 37646517Paper 34842841Paper 34716040Paper 34427503Paper 34232076Paper 30971707Paper 30580014Paper 29942084Paper 29306353Paper 29133347Paper 29104143Paper 26512047Paper 26409202Paper 26283553Paper 26154421Paper 26149863Paper 26055740Paper 25991682Paper 25722294Paper 25561705Paper 25392355Paper 25144724Paper 25114012Paper 25065707Paper 24786645Paper 24762744Paper 24686738Paper 24516685Paper 24394479Paper 16988262
Abstract
PROJECT SUMMARY Cholera is a severe dehydrating illness of humans. It is endemic in over 50 countries and causes 3 to 5 million cases a year, resulting in approximately 100,000 deaths. Currently available cholera vaccines have shortcomings. They are often poorly immunogenic in children under the age of 5 years, and often do not induce robust long-term memory responses in immunologically naïve populations. We provide strong preliminary data that antibodies targeting O-specific polysaccharide (OSP) affect Vibrio cholerae and are associated with protection against cholera. We here propose an international clinical study approach to investigate the impact of OSP-specific antibodies on V. cholerae.
View original record on NIH RePORTER →